The requirement for PKCε to facilitate the efficient division of that subset of tumour cells with a defective Topo2-dependent G2 arrest as observed on treatment with ICRF193, suggests that this very druggable protein is a rational target in this subset of cancer settings. Here, PRKCE is linked to cancer.